Drugs / anti-CD7 CAR-pNK cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02742727 | Mar 2016 → Mar 2017 | T-cell large granular lymphocyte leukemia, T-cell prolymphocytic leukemia, acute myeloid leukemia, angioimmunoblastic T-cell lymphoma +4 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-CD7 CAR-pNK cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02742727 ↗ |
| Modality | Cell therapy | “The allogeneic NK cells (NK-92 cell line for clinical use) are engineered to contain anti-CD7 attached to TCRzeta, CD28 and 4-1BB signaling domains.” NCT02742727 ↗ |
| Route | Other | “by infusion” NCT02742727 ↗ |